Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02262845
Other study ID # 90987979
Secondary ID
Status Completed
Phase N/A
First received October 9, 2014
Last updated March 20, 2017
Start date February 2015
Est. completion date September 2016

Study information

Verified date March 2017
Source Boston Scientific Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to document clinical utility and distribution of indications for short term pancreatic stenting, and stent type preference by indication at tertiary referral centers with expertise in pancreatic endotherapy.


Description:

The study is designed as an all-comer, prospective, multi-center, consecutive cohort series, open-label study.

Detailed objective: To confirm the clinical utility of Advanix™ Pancreatic Stents when used per standard of practice to facilitate pancreatic duct drainage in the following clinical presentations:

- Group A: PEP Risk - In subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP)

- Group B: Impaired Pancreatic Duct Drainage - In subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after ESWL or before pancreatic surgery

- Group C: Pancreatic Duct Leak - In subjects with a pancreatic duct leak

- Group D: Post Pancreatic Surgery - In subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy

- Group E: Other - In subjects with other indications


Recruitment information / eligibility

Status Completed
Enrollment 246
Est. completion date September 2016
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subjects age 18 or older.

2. Subjects who require pancreatic drainage and are amenable to endoscopic techniques.

3. Subjects willing and able to comply with the study procedures and follow up schedule and willing to provide written informed consent to participate in the study.

4. Subjects satisfying at least one of the following clinical presentations:

1. high risk of acute pancreatitis post ERCP

2. impaired pancreatic duct drainage and pain associated with a pancreatic duct dominant stricture and/or stones and/or sludge/debris, possibly before ESWL or before pancreatic surgery

3. need to maintain proper pancreatic duct drainage in the presence of a pancreatic duct leak

4. need to maintain proper pancreatic duct drainage after surgical resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy

Exclusion Criteria:

1. Subjects for whom endoscopic techniques are contraindicated.

2. Subjects with known sensitivity to any components of the stents or delivery systems.

3. Subjects with coagulopathy outside of what is deemed acceptable for ERCPs per standard of practice

4. Subjects who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor.

5. Subjects unable or refusing to comply with the follow-up schedule including subject living at such a distance from the investigational center that attending follow-up visits would be unusually difficult or burdensome.

Study Design


Intervention

Device:
The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
Used to drain pancreatic ducts

Locations

Country Name City State
Germany Evangelisches Krankenhaus Dusseldorf Duesseldorf
India Asian Institute of Gastroenterology Somajiguda Hyderabad
Netherlands Erasmus Medical Center Rotterdam
United States Medical University of South Carolina Charleston South Carolina
United States Methodist Dallas Medical Center Dallas Texas
United States Temple University School of Medicine Philadelphia Pennsylvania
United States Virginia Mason Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Boston Scientific Corporation

Countries where clinical trial is conducted

United States,  Germany,  India,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Success: Group A (PEP Risk) Absence of acute pancreatitis from stent placement through 48 hours post stent placement Stent placement through 48 hours post stent placement
Primary Clinical Success: Group B (Impaired Pancreatic Duct Drainage) Absence of acute pancreatitis from stent placement through stent removal and, where applicable, improvement of pain at stent removal compared to baseline Stent placement through stent removal
Primary Clinical Success: Group C (Pancreatic Duct Leak): Resolution of pancreatic duct leak at stent removal Stent Removal
Primary Clinical Success: Group D (Post Pancreatic Surgery) Absence of pancreatic duct leak and stricture at stent removal Stent Removal
Primary Clinical Sucess: Group E (Other) Resolution of the indication for stent placement at stent removal Stent Removal
Secondary Serious Adverse Events and all occurrences of acute pancreatitis Occurrence and severity of serious adverse events related to the stent and/or the stent placement and/or stent removal procedures as applicable and all occurrences of acute pancreatitis. Through end of study
Secondary Technical Success Evaluation of technical success defined as the ability to place the stent in a satisfactory position in the main pancreatic duct as determined by fluoroscopy. Stent Placement
Secondary Ease of use Evaluation of ease of use documenting overall ease of placement, pushability of stent and ability to visualize the stent fluoroscopically. Stent Placement
Secondary Removability Evaluation of removability defined as ability to remove the Advanix stent endoscopically without serious stent removal related adverse events. Stent Removal
Secondary Stent Migration Documentation of stent migration rates overall, by Group, and by stent type Through end of study
Secondary Reintervention Evaluation of the occurrence of reintervention defined as any type of endoscopic, percutaneous, or surgical procedure to aid drainage of the pancreas after initial stent placement through end of follow-up. Through end of study
Secondary Stent type preference Documenting stent type preference by subject presentation and pancreatic plastic stenting indication. Stent Placement
See also
  Status Clinical Trial Phase
Completed NCT04546867 - Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal N/A
Terminated NCT02241512 - IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis Phase 2
Completed NCT00222092 - Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers Phase 4
Completed NCT05310409 - PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
Not yet recruiting NCT06260878 - Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis Phase 4
Not yet recruiting NCT04770857 - Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
Completed NCT02641561 - Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis Phase 3
Active, not recruiting NCT04145336 - 7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients N/A
Completed NCT03629600 - Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis Phase 2/Phase 3
Recruiting NCT03756116 - Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide N/A
Recruiting NCT05664074 - Rectal Indomethacin vs Intravenous Ketorolac Phase 4
Completed NCT02308891 - A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis N/A
Recruiting NCT05336630 - Study of Forceps Cannulation During ERCP N/A
Recruiting NCT05857514 - Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis N/A
Recruiting NCT05267379 - An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
Recruiting NCT05947461 - Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac N/A
Completed NCT03098082 - Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis N/A
Recruiting NCT02839356 - Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis Phase 4
Recruiting NCT02830984 - ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP N/A
Completed NCT01673763 - Post-ERCP Pancreatitis Prevention by Stent Insertion N/A